Corvus Pharmaceuticals, Inc. (CRVS) is a publicly traded Healthcare sector company. As of November 17, 2026, CRVS trades at $10.26 with a market cap of $897.52M and a P/E ratio of -55.55. CRVS moved -3.20% today. Year to date, CRVS is +44.88%; over the trailing twelve months it is +20.92%. Its 52-week range spans $2.54 to $26.95. Analyst consensus is strong buy with an average price target of $28.75. Rallies surfaces CRVS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Three ALPS patients improve; atopic dermatitis results show 75% achieved EASI75: Three patients in Corvus Pharmaceuticals’ Phase 2 soquelitinib trial for ALPS reported improved symptoms after one year, and all three discontinued background medications, including steroids. Phase 1 atopic dermatitis results showed 75% achieved EASI75, with no serious adverse events; cash runway extends into the second quarter of 2028.
| Metric | Value |
|---|---|
| Price | $10.26 |
| Market Cap | $897.52M |
| P/E Ratio | -55.55 |
| EPS | $-0.19 |
| Dividend Yield | 0.00% |
| 52-Week High | $26.95 |
| 52-Week Low | $2.54 |
| Volume | 126 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-15.28M |
| Gross Margin | 0.00% |
4 analysts cover CRVS: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $28.75.